Press release
Lawsuit filed for Investors in shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)
A lawsuit was filed on behalf of investors in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares.
Investors who purchased a shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and for certain investors are short and strict deadlines running. Deadline: June 14, 2022. NASDAQ: AUPH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Canada based Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.
On February 28, 2022, Aurinia Pharmaceuticals Inc. announced its financial results for the quarter and full year ended December 31, 2021. Among other items, Aurinia reported a year-over-year revenue decline and announced a lower-than-expected sales outlook for 2022.
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) declined from $33.97 per share on November 3, 2021, to as low as $9.91 per share on March 15, 2022.
The plaintiff claims that between May 7, 2021 and February 25, 2022, the Defendants made false and/or misleading statements and/or failed to disclose that Aurinia Pharmaceuticals Inc was experiencing declining revenues, that Aurinia Pharmaceuticals Inc's 2022 sales outlook for LUPKYNIS would fall well short of expectations, that accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects, that as a result, the Company had overstated its financial position and/or prospects for 2022, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) here
News-ID: 2607591 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Aurinia
Lupus Nephritis Market Growth to Accelerate in Forecast Period (2024-2034), Delv …
The Lupus Nephritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lupus Nephritis pipeline products will significantly revolutionize the Lupus Nephritis market dynamics.
DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United…
Lupkynis Market is Expected to Show a Healthy Growth Rate During the Study Perio …
(Las Vegas, Nevada, United States) "DelveInsight's "LUPKYNIS Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LUPKYNIS for lupus nephritis in the seven major markets. A detailed picture of the LUPKYNIS for lupus nephritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed…
Investigation announced for Investors in shares of Aurinia Pharmaceuticals Inc. …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Aurinia Pharmaceuticals Inc..
Investors who are current long term investors in Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: AUPH stocks follows a lawsuit filed against Aurinia…
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Investor Notice: Deadline in Lawsuit …
A deadline is coming up on June 14, 2022 in the lawsuit filed for certain investors of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) over alleged securities laws violations by Aurinia Pharmaceuticals Inc.
Investors who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) have certain options and there are strict and short deadlines running. Deadline: June 14, 2022. NASDAQ: AUPH stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Investors in Aurinia Pharmaceuticals Inc. (NASDAQ: A …
Aurinia Pharmaceuticals Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Aurinia Pharmaceuticals Inc. regarding its business, its prospects and its operations were materially false…
Targeted Therapeutics Market Trends and Growth During 2021-2027 | Aurinia Pharma …
The Global Targeted Therapeutics market size is growing at a CAGR of 6.7% over the forecast period of 2021-2026.
Targeted therapy may be described as a treatment contemplated in the treatment of cancer. Targeted cancer therapy is also limited to molecularly targeted drugs/therapeutics. These treatments use precision drugs that identify and kill cancer cells in the body without affecting normal cells. Most targeted therapies do not resemble standard practices like chemotherapy…
